![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
![Publish Open Access Finland]({"type":"image" , "src" : "/sda/110396/JournalAd-OA-Agreements.gif"})
![Offer for the Toxicology Open Access!]({"type":"image" , "src" : "/sda/110939/OA-Toxicology-F1000.jpg"})
Abstract
Abstract
Context: A proteomic analysis has proposed fetuin-A (alpha-2-HS-glycoprotein) as a new potential marker for pancreatic cancer (PC).
Objective: Circulating fetuin-A levels in patients with PC.
Methods: Serum fetuin-A was measured in 81 cases with PC and 81 matched controls before the initiation of any treatment.
Results: Serum fetuin-A was not independently associated with the presence of PC. Although there was a trend with higher fetuin-A levels across PC stages, comparisons of fetuin-A in patients within different PC prognostic stages revealed no differences.
Conclusions: Circulating fetuin-A was similar between patients and controls and was not associated with the disease severity.